Previous 10 | Next 10 |
2023-12-27 12:23:36 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Cingulate Inc (NASDAQ...
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal ...
2023-12-27 09:57:20 ET DENVER, Colo., Dec. 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; First Wave BioPharma Inc (NASDAQ: FWBI), Coherus BioSciences Inc (NASDAQ: CHRS), Opthea Ltd (NASDAQ: OPT), Ci...
2023-12-27 08:27:59 ET First Wave BioPharma FWBI +107% on plans to sell niclosamide program . Cingulate ( CING ) +89% . Cytokinetics CYTK +53% on positive Phase 3 data for heart disease therapy . Jet.AI ( JTAI ) +38% . Cohe...
2023-12-27 07:49:33 ET DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- First Wave BioPharma, Inc. (NASDAQ: FWBI) stated, this morning, that it entered into a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD), which will ...
2023-12-27 07:43:36 ET More on First Wave BioPharma First Wave BioPharma files for stock and warrants offering, size not disclosed First Wave BioPharma CFO discloses sale of 1,676 shares Seeking Alpha’s Quant Rating on First Wave BioPharma Historical e...
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointe...
Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma’s late-stage gastrointestinal (GI) disease clinical pipeline A concurrent institutional investment and a strategic U.S. license agreement with a global pharmaceutical ...
2023-12-14 11:23:20 ET More on First Wave BioPharma First Wave BioPharma files for stock and warrants offering, size not disclosed First Wave BioPharma CFO discloses sale of 1,676 shares For further details see: First Wave BioPharma approves a 1-for-20 reverse st...
BOCA RATON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma,” “First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic the...
News, Short Squeeze, Breakout and More Instantly...
First Wave BioPharma Inc. Company Name:
FWBI Stock Symbol:
NASDAQ Market:
Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is “ENTO” effective May 17, 2024 BOCA RATON, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Entero Ther...
BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...